We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

brain scan image via Shutterstock

New MS drug now available in Republic

The drug has been made available through one HSE scheme.

A PHARMACEUTICAL COMPANY has today announced that an oral treatment for people with active relapsing-remitting multiple sclerosis is now available in the Republic of Ireland.

The drug, Aubagio, has been described as “an exciting development for the MS community” by Chief Executive of MS Society Ireland, Ava Battles.

It is the first oral, once-daily, first-line medicine for treatment of relapsing-remitting MS and offers an alternative to repeated injections.

As of the start of this month, the drug has been approved for the HSE’s High Tech drug scheme for reimbursement.

“MS Ireland believes people with MS should have access to all and any appropriate and licensed treatments that would improve or assist in the management of their condition,” Battles commented.

Relapsing-remitting MS affects about 85% of those diagnosed with MS. Approximately 250 people are diagnosed with MS every year in Ireland with 8,000 in total directly affected by the disease.

Read: Medicinal marijuana drug means end to buying drugs on the street>

Read: Calls made for “wonder MS drug” to be made available by HSE>

Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

Your Voice
Readers Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.